The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study.
Yael P. Mosse
Research Funding - Pfizer
Frank M. Balis
No relevant relationships to disclose
Megan S Lim
No relevant relationships to disclose
Julie Laliberte
No relevant relationships to disclose
Stephan D Voss
No relevant relationships to disclose
Elizabeth Fox
No relevant relationships to disclose
Rochelle Bagatell
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose
Peter C. Adamson
No relevant relationships to disclose
Ashish M Ingle
No relevant relationships to disclose
Charlotte H Ahern
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose